AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial

AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial

Abstract Objectives Phase I - To determine the optimal dose of each candidate (or combination of candidates) entered into the platform. Phase II - To determine the efficacy and safety of each candidate entered into the platform, compared to the current Standard of Care (SoC), and recommend whether i...

Full description

Bibliographic Details
Main Authors: Gareth Griffiths, Richard Fitzgerald, Thomas Jaki, Andrea Corkhill, Ellice Marwood, Helen Reynolds, Louise Stanton, Sean Ewings, Susannah Condie, Emma Wrixon, Andrea Norton, Mike Radford, Sara Yeats, Jane Robertson, Rachel Darby-Dowman, Lauren Walker, Saye Khoo, on behalf of the UK NIHR community
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Trials
Subjects:
COVID-19
Randomised controlled trial
Platform study
Master protocol
Phase I/II
Bayesian
Online Access:http://link.springer.com/article/10.1186/s13063-020-04473-1

Internet

http://link.springer.com/article/10.1186/s13063-020-04473-1

Similar Items